Table 2

Metabolic parameters

Variable

Control

DM+NS

Pre-treatment

DM+LC(L)

DM+LC(H)

Body Weight (g)

44.4 ± 3.4

40.1 ± 2.1

32.0 ± 2.8^××##

40.3 ± 2.0

41.8 ± 5.6

Liver weight (g)

1.3 ± 0.3

2.4 ± 0.5**

2.0 ± 0.4*

1.9 ± 0.3*^#

1.8 ± 0.2^#

Relative liver weight

0.04 ± 0.01

0.06 ± 0.01**

0.06 ± 0.01

0.05 ± 0.00^#

0.05 ± 0.00^##

FFA in liver (L/g·cm)

1.7 ± 0.1

2.0 ± 0.3*

1.8 ± 0.2

1.9 ± 0.3

1.8 ± 0.1

TG in liver (mmol/L)

0.23 ± 0.04

1.16 ± 0.6**

0.34 ± 0.2^##

0.55 ± 0.09^#

0.48 ± 0.1^##

TG in plasma (mmol/L)

1.2 ± 0.1

3.9 ± 2.3**

1.7 ± 0.6

2.2 ± 1.0

1.6 ± 0.4

LC in liver (μmol/L)

16.9 ± 3.4

11.2 ± 2.6*

12.1 ± 3.1

14.9 ± 1.9

12.6 ± 4.1

ALC in liver (μmol/L)

1.0 ± 0.2

0.8 ± 0.3

1.0 ± 0.7

1.4 ± 0.2

2.3 ± 0.9**^##

LC/ALC

16.9 ± 4.7

16.6 ± 5.9

15.4 ± 6.6

11.3 ± 2.8

5.6 ± 1.5**^##

Control: control group, DM+NS: diabetic group, pre-treatment: preventive group, DM+LC (L): low-dose therapeutic group, DM+LC (H): high-dose therapeutic group. All values are expressed as the mean ± S.E. using the repeated measures method. *P < 0.05, **P < 0.01 (compared to control group), ^#P < 0.05, ^##P < 0.01 (compared to diabetic group).

Xia et al. Diabetology & Metabolic Syndrome 2011 3:31   doi:10.1186/1758-5996-3-31